Related Experiment Video
Updated: Jun 16, 2025
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Real-World Treatment and Outcomes in ALK-Rearranged NSCLC: Results From a Large U.S.-Based Database
Grace Chazan1, Fanny Franchini2,3, Roma Shah4
1Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
Introduction:
ALK-rearranged advanced NSCLC (aNSCLC) represents 4% of all NSCLCs, and multiple ALK-targeted therapies (ALK-inhibitors) are now available for use. Little is known about changes in treatment patterns, or how prognostic factors and sequence of therapy may impact overall survival in the real-world setting. We aim to describe initial and subsequent treatments used, survival outcomes, prognostic factors, and the impact of treatment on overall survival in the largest (N = 739) real-world cohort of patients with ALK+ aNSCLC reported in the literature.
Methods:
Retrospective observational cohort study with data drawn from a U.S.-based electronic health record-derived, deidentified database. Eligible patients were diagnosed with ALK+ aNSCLC between 2011-2020 and were treated in multiple different cancer clinics and across multiple geographic regions throughout the United States.
Results:
From a cohort of 63,667 patients with aNSCLC, 739 patients with ALK+ NSCLC were eligible for analysis, median age was 63 years, 54% patients were female, and 85% were managed in community setting. More than 168 different treatment sequences were observed, and treatment utilization changed over time. Cohort median overall survival was 37 months (95% confidence interval: 33-45). Positive prognostic factors were as follows: never-smoking history, younger age, treatment in an academic setting, and initial early stage at diagnosis. Initial treatment with a second-generation ALK-inhibitor was associated with improved survival compared with chemotherapy.
Conclusions:
For people with ALK+ aNSCLC, this study has identified several important clinical prognostic factors and is practice affirming; first-line treatment with a second-generation ALK-inhibitor improves survival compared with chemotherapy.
Insights
For advanced ALK-positive NSCLC patients, real-world data show that initial treatment with a second-generation ALK-inhibitor improves overall survival compared to chemotherapy. This study also identified key prognostic factors influencing outcomes in this patient population.
Area of Science:
- Oncology
- Clinical Research
- Pharmacology
Background:
- Anaplastic Lymphoma Kinase (ALK)-rearranged advanced Non-Small Cell Lung Cancer (aNSCLC) accounts for 4% of NSCLC cases.
- Multiple ALK-inhibitors are available, but real-world data on treatment patterns and survival impact are limited.
- Understanding prognostic factors and treatment sequences is crucial for optimizing patient outcomes.
Purpose of the Study:
- To describe treatment patterns, survival outcomes, and prognostic factors in a large real-world cohort of ALK-positive aNSCLC patients.
- To evaluate the impact of initial and subsequent therapies on overall survival.
- To identify factors influencing survival in ALK-positive aNSCLC.
Main Methods:
- Retrospective observational cohort study using deidentified electronic health records from U.S. cancer clinics.
- Analysis of 739 patients diagnosed with ALK-positive aNSCLC between 2011 and 2020.
- Examination of over 168 distinct treatment sequences and associated survival data.
Main Results:
- Median overall survival for the cohort was 37 months.
- Positive prognostic factors included never-smoking history, younger age, academic treatment setting, and early diagnosis stage.
- Initial treatment with a second-generation ALK-inhibitor was associated with improved survival versus chemotherapy.
- Treatment utilization patterns evolved over the study period.
Conclusions:
- First-line treatment with a second-generation ALK-inhibitor significantly improves survival in ALK-positive aNSCLC compared to chemotherapy.
- Identified clinical prognostic factors provide valuable insights for patient management.
- This study affirms the practice of using second-generation ALK-inhibitors as initial therapy.
